Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma

Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06780475

Acronym

VIRASKIN

Enrollment

Registered

2025-01-17

Start date

2025-05-27

Completion date

2027-05-31

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Merkel Cell Carcinoma of Skin

Keywords

Merkel Cell Carcinoma of Skin

Brief summary

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Detailed description

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients \>= 18 years old; * Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up; * Informed for the study and no-opposed for participation; * Affiliated with a social security scheme or in an equivalent situation.

Exclusion criteria

* Patients ongoing another interventional clinical trial; * Patients under guardianship or trusteeship; * Pregnancy or breastfeed; * Patients refusal.

Design outcomes

Primary

Measure	Time frame	Description
Anti-MCPyV functionality	Day 0 and Day 4	Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.

Countries

France

Contacts

Primary ContactAstrid Blom, MD

astrid.blom@aphp.fr+33 (01) 49 09 44 82

Backup ContactYassine Taoufik, MD, PhD

yassine.taoufik@aphp.fr

Outcome results